These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1006321)

  • 21. High-performance liquid chromatographic determination of canrenone, a major metabolite of spironolactone, in body fluids.
    Neurath GB; Ambrosius D
    J Chromatogr; 1979 Jun; 163(2):230-5. PubMed ID: 541378
    [No Abstract]   [Full Text] [Related]  

  • 22. A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations, including preliminary data on two spironolactone metabolites.
    Tidd MJ; Collins WT; Chamberlain J
    J Int Med Res; 1976; 4(2):86-95. PubMed ID: 1037443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of spironolactone after a single dose: evaluation of the true canrenone serum concentrations during 24 hours.
    Merkus FW; Overdiek JW; Cilissen J; Zuidema J
    Clin Exp Hypertens A; 1983; 5(2):239-48. PubMed ID: 6831747
    [No Abstract]   [Full Text] [Related]  

  • 24. [Biological availability of spironolactone in two different galenic forms (author's transl)].
    Rameis H; Hitzenberger G; Horwatitsch H
    Dtsch Med Wochenschr; 1979 Jun; 104(24):881-3. PubMed ID: 446311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.
    Karim A; Zagarella J; Hutsell TC; Dooley M
    Clin Pharmacol Ther; 1976 Feb; 19(2):177-82. PubMed ID: 1261155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids.
    Steimer W; Müller C; Eber B
    Clin Chem; 2002 Mar; 48(3):507-16. PubMed ID: 11861441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
    DeFrance A; Armbruster D; Petty D; Cooper KC; Dasgupta A
    Ther Drug Monit; 2011 Feb; 33(1):128-31. PubMed ID: 21079546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
    Vergin H; Nuss U; Strobel K
    Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparative bioavailability of two forms of spironolactone. Rationalization applied to dosage (author's transl)].
    d'Athis P; Richard MO; de Lauture D; Rey E; Bouvier d'Yvoire M; Clement E; Olive G
    Therapie; 1981; 36(4):443-9. PubMed ID: 7292427
    [No Abstract]   [Full Text] [Related]  

  • 30. Quantitation of spironolactone and its metabolite, canrenone, in human serum by thin-layer spectrofluorimetry.
    van der Merwe PJ; Müller DG; Clark EC
    J Chromatogr; 1979 Apr; 171():519-21. PubMed ID: 546864
    [No Abstract]   [Full Text] [Related]  

  • 31. Simultaneous separation and rapid determination of spironolactone and its metabolite canrenone in different pharmaceutical formulations and urinary matrices by capillary zone electrophoresis.
    Li L; Huang Y; Zhao W; Zhang G; Zhang H; Chen A
    J Sep Sci; 2016 Jul; 39(14):2869-75. PubMed ID: 27257119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spironolactone. II. Bioavailability.
    Karim A; Zagarella J; Hutsell TC; Chao A; Baltes BJ
    Clin Pharmacol Ther; 1976 Feb; 19(2):170-6. PubMed ID: 1261154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biotransformations of the cardiovascular drugs mexrenone and canrenone.
    Preisig CL; Laakso JA; Mocek UM; Wang PT; Baez J; Byng G
    J Nat Prod; 2003 Mar; 66(3):350-6. PubMed ID: 12662091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone.
    Ho PC; Bourne DW; Triggs EJ; Smithurst BA
    Eur J Clin Pharmacol; 1984; 27(4):435-9. PubMed ID: 6519150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo availability of spironolactone from oral dosage forms.
    Chao AY; Sanvordeker DR; Zagarella J; Mattes K; Nicholova B; Karim A
    J Pharm Sci; 1976 Nov; 65(11):1630-4. PubMed ID: 993995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spironolactone metabolite causes falsely increased progesterone in the Abbott Architect immunoassay.
    Sarpong KAN; Hee Kim S; McCartney CR; Wiencek JR; Bazydlo LAL
    Clin Biochem; 2024 Apr; 126():110747. PubMed ID: 38484829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors influencing comparative bioavailability of spironolactone tablets.
    Clarke JM; Ramsay LE; Shelton JR; Tidd MJ; Murray S; Palmer RF
    J Pharm Sci; 1977 Oct; 66(10):1429-32. PubMed ID: 579186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spironolactone and potassium canrenoate metabolism.
    Gardiner P
    Lancet; 1985 Dec 21-28; 2(8469-70):1432. PubMed ID: 2867429
    [No Abstract]   [Full Text] [Related]  

  • 39. Suppression by the spironolactone metabolite canrenone of plasma testosterone in man.
    Erbler HC
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 285(4):403-6. PubMed ID: 4280523
    [No Abstract]   [Full Text] [Related]  

  • 40. [Studies of biological availability. A critical assessment based on a study of spironolactone preparations].
    Rameis H; Bacher S
    Wien Med Wochenschr; 1988 Apr; 138(6-7):156-60. PubMed ID: 3394332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.